Center Ventures
VC Fund
Taipei, Taiwan
Center Ventures is a VC fund in Taipei focused on Biotechnology and Pharmaceutical. Founded as a pharmaceutical company, they are equipped with practical experience and business expertise in biotechnology. Their familiarity with the industry value chain and ecosystem, along with complete expert network and resource integration capabilities, make us the most professional biotechnology incubator platform in Asia Pacific.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 29%
Last updated:
For AI agents: llms.txt
Industries Center Ventures invests in
Stages Center Ventures invests in
Countries Center Ventures invests in
Round sizes
Round size
- Series A
- $24M–$62M
- Series B
- $100M–$102M
Investment Focus
Industry
- Biotechnology 4 (57%)
- Pharmaceutical 3 (43%)
- Medical 2 (29%)
- Biopharma 2 (29%)
- Genetics 1 (14%)
Stage
- Series A 2 (29%)
- Series B 2 (29%)
- Seed 1 (14%)
- Series C 1 (14%)
Country
- China 4 (57%)
- Taiwan 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Hipot
|
Hipot is a technological innovation company dedicated to providing hydrogen fuel cell commercial vehicle transportation solutions. | $62M / Series A / Mar 24, 2025 | |
Baoji Pharmaceutical
|
Baoji Pharmaceutical is a biopharma R&D manufacturer, a Sino-foreign joint biopharmaceutical enterprise integrating drug R&D and production. | Series C / Dec 01, 2024 | |
|
Baoji Pharmaceutical
|
Baoji Pharmaceutical is a biopharma R&D manufacturer, a Sino-foreign joint biopharmaceutical enterprise integrating drug R&D and production. | Series C / Jul 19, 2024 | |
GenEditBio
|
GenEditBio is a biotech company that specializes in providing curative gene editing based solutions for genetic diseases. | $90M / Seed / Apr 04, 2024 | |
|
Baoji Pharmaceutical
|
Baoji Pharmaceutical is a biopharma R&D manufacturer, a Sino-foreign joint biopharmaceutical enterprise integrating drug R&D and production. | $100M / Series B / Aug 26, 2022 | |
Immunwork
|
Immunwork develops innovative drugs that combine targeting and effector functions to enhance efficacy and safety. The company focuses on creating ultralong-acting analogues, such as TE-8214, an octreotide derivative, and TE-8035, a modified human insulin. Immunwork's drug pipeline addresses immune system diseases and leverages a proprietarytechnology platform. The company is involved in clinical trials to validate its therapeutic solutions. | $23.7M / Series A / Mar 08, 2022 | |
TOT BIOPHARM
|
TOT BIOPHARM is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative oncology drugs and therapies. Our mission is to build a leading brand name of oncology treatments trusted by patients and their families as well as medical professionals in China. | $102M / Series B / Aug 08, 2018 |
Co-Investors
Finnova Capital
2 deals together
Qiming Venture Partners
2 deals together
99Fund
1 deal together
Cathay Capital
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Center Ventures invest in?
Center Ventures invests primarily in Biotechnology, Pharmaceutical and Medical startups, most often at Series A and Series B stage. Most of the 7 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Center Ventures's check size?
Center Ventures typically joins rounds of $24M–$62M at Series A and $100M–$102M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Center Ventures participates in.
When did Center Ventures last invest?
The most recent investment recorded for Center Ventures closed in Mar 2025. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
